Atossa Therapeutics, Inc. (ATOS.MX)

Compare

14.70

-1.30

(-8.13%)

At close: 1:12:44 PM CST

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Contro

GlobeNewswire 26 days ago

ATOS
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board’s (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the “’334 patent”). Atossa is disappointed with the PTAB’s decision finding all challenged claims in the ’334 p

GlobeNewswire last month

ATOS
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows: To our valued shareholders, As we reflect on 2024, I am proud to share t

GlobeNewswire last month

ATOS
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, commends the U.S. Surgeon General for issuing a crucial Advisory that describes the scientific evidence for the causal link between alcohol consumption and increased cancer risk, particularly breast cancer in women. The Surgeon General’s Advisory reveals that alcohol consumption cont

GlobeNewswire last month

ATOS
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.

Zacks 2 months ago

ATOS

GILD
Atossa Therapeutics to present poster on Z-endoxifen at SABCS

Atossa Therapeutics (ATOS) announced data describing the discovery of compounds that may be synergistic with (Z)-endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium, SABCS, on December 13, 2024. The data suggest that combination therapies with (Z)-endoxifen and agents targeting topoisomerase, CDK, mTOR/PI3K and AKT have potential in the treatment of breast cancer b

TipRanks 2 months ago

ATOS
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer TreatmentsSEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced data describing

GlobeNewswire 2 months ago

ATOS
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium SEATTLE, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced full results from its Phase 2 KARISMA-Endoxifen trial conducted at the Karolinska Institute in Stockholm, Sweden. The data, wh

GlobeNewswire 2 months ago

ATOS
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024). EVANGELINE is a randomized Ph

GlobeNewswire 2 months ago

ATOS
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Novel Compounds Demonstrate Promising Anti-Tumor Activity in Estrogen Receptor-Positive (ERα+) Breast Cancer, Including Endocrine-Resistant TumorsSEATTLE, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the presentation of research investigating the anti-cancer activ

GlobeNewswire 2 months ago

ATOS
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast CancerSEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that a poster detailing the anti-cancer activity of (Z)-endoxifen-related compounds in estrogen receptor alpha-positive (ERα+) breast cancer will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research in Toronto from December 9-11,

GlobeNewswire 3 months ago

ATOS
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen’s ability to significantly reduce mammographic breast density to be featured at conferenceSEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that five abstracts featuring data on (Z)-

GlobeNewswire 3 months ago

ATOS
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

Here is how Intuitive Surgical, Inc. (ISRG) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.

Zacks 3 months ago

ISRG

ATOS
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical tria

GlobeNewswire 3 months ago

ATOS
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa’s Mission in Developing Innovative Breast Cancer TherapiesSEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership ro

GlobeNewswire 3 months ago

ATOS
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today released positive topline data from the KARISMA-Endoxifen Phase 2 study of (Z)-endoxifen in premenopausal women with mammographic breast densit

GlobeNewswire 3 months ago

ATOS
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial Low dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 and FTV Biomarkers SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today released a preliminary analysis from a phase 2 trial of (Z)-endoxifen as part of the I-SPY 2 Endocrine Optimization

GlobeNewswire 3 months ago

ATOS
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks 4 months ago

ATOS

CAH
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial in

GlobeNewswire 4 months ago

ATOS
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast can

GlobeNewswire 4 months ago

ATOS

Performance Overview

Return	ATOS.MX	S&P 500
YTD	-30.00%	-0.54%
1-Year	-18.33%	+13.87%
3-Year	-43.46%	+34.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Atossa Therapeutics, Inc. (ATOS.MX)

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Atossa Therapeutics to present poster on Z-endoxifen at SABCS

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Performance Overview